AnPac Bio-Medical Science Co Ltd - ADR Share

$0.33

0.90%

Nasdaq, Mon, Jul 01 2024

ISIN

US03635R1077

Symbol

ANPC

Reports

Quarter | Year

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

AnPac Bio-Medical Science Co Ltd - ADR Share price

$0.33

-224.67 99.85% 5Y

Nasdaq, Closing price Mon, Jul 01 2024

-0.00 0.90%

ISIN

US03635R1077

Symbol

ANPC

Reports

Quarter | Year

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$4.82m
Enterprise Value	$7.47m
PER (TTM) P/E ratio	negative
EV/Sales (TTM) EV/Sales	4.39
P/S ratio (TTM) P/S ratio	2.84
P/B ratio (TTM) P/B ratio	0.23
Sales growth (TTM) Sales growth	-21.24%
Turnover (TTM) Turnover	$1.70m
EBIT (operating result TTM) EBIT	$-13.95m
Cash position	$70.00k
EPS (TTM) EPS	$-4.21
Short interest	0.31%

As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.

Get Started for Free Today

AnPac Bio-Medical Science Co Ltd - ADR Share analysis

Unlock Scores for Free

??

Financial data from AnPac Bio-Medical Science Co Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter Annually

Assets

Dec '22
Current assets	1.97 1.97
Cash position	0.27 0.27
Claims	0.88 0.88
Inventories	0.03 0.03
Other current assets Other current assets Current assets	0.79 0.79

Fixed assets	3.85 3.85
Property, plant and equipment	3.51 3.51
Financial assets	0.16 0.16
Intangible assets	0.03 0.03
Other fixed assets Other assets Fixed assets	0.16 0.16


Total assets	5.82 5.82

Liabilities

Dec '22
Equity	-1.35 -1.35

Debt capital	7.17 7.17
Current liabilities	6.08 6.08
Non-current liabilities	1.09 1.09


Total capital	5.82 5.82

Figures in millions USD.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Subscribe to news free of charge

AnPac Bio-Medical Science Co Ltd - ADR Share News

Neutral

PRNewsWire

●

about one year ago

Fresh2 Group Ltd. Announces Nasdaq Ticker Symbol Change from 'ANPC' to 'FRES'

Ticker symbol change effective at the market open May 22, 2023 NEW YORK , May 19, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd.

Neutral

PRNewsWire

●

about one year ago

Fresh2 Files Annual Report on Form 20-F for Fiscal Year 2022

NEW YORK , May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, ...

Neutral

PRNewsWire

●

about one year ago

Fresh2 Reports Fiscal Year 2022 Annual Financial Results

NEW YORK , May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, ...

More AnPac Bio-Medical Science Co Ltd - ADR News

Company profile

Anpac Bio-Medical Science Co., Ltd., a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.

Head office	Virgin Islands, British
CEO	Hao Yu
Employees	75
Founded	2010
Website	www.anpacbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now